Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer: A complicated decision

Kelsey Lewis, Karen H. Lu, Amber M. Klimczak, Samuel C. Mok

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.

Original languageEnglish (US)
Article number57
JournalCancers
Volume10
Issue number2
DOIs
StatePublished - Feb 21 2018

Fingerprint

Ovarian Neoplasms
Mutation
Early Detection of Cancer
Guidelines
Therapeutics
Research

Keywords

  • BRCA
  • CA-125
  • Ovarian cancer
  • Risk-reducing surgery
  • Screening guidelines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer : A complicated decision. / Lewis, Kelsey; Lu, Karen H.; Klimczak, Amber M.; Mok, Samuel C.

In: Cancers, Vol. 10, No. 2, 57, 21.02.2018.

Research output: Contribution to journalReview article

Lewis, Kelsey ; Lu, Karen H. ; Klimczak, Amber M. ; Mok, Samuel C. / Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer : A complicated decision. In: Cancers. 2018 ; Vol. 10, No. 2.
@article{51241ccbf1164ee586de0292b9f07aed,
title = "Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer: A complicated decision",
abstract = "Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.",
keywords = "BRCA, CA-125, Ovarian cancer, Risk-reducing surgery, Screening guidelines",
author = "Kelsey Lewis and Lu, {Karen H.} and Klimczak, {Amber M.} and Mok, {Samuel C.}",
year = "2018",
month = "2",
day = "21",
doi = "10.3390/cancers10020057",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer

T2 - A complicated decision

AU - Lewis, Kelsey

AU - Lu, Karen H.

AU - Klimczak, Amber M.

AU - Mok, Samuel C.

PY - 2018/2/21

Y1 - 2018/2/21

N2 - Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.

AB - Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.

KW - BRCA

KW - CA-125

KW - Ovarian cancer

KW - Risk-reducing surgery

KW - Screening guidelines

UR - http://www.scopus.com/inward/record.url?scp=85042676582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042676582&partnerID=8YFLogxK

U2 - 10.3390/cancers10020057

DO - 10.3390/cancers10020057

M3 - Review article

AN - SCOPUS:85042676582

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

M1 - 57

ER -